Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies.

ABSTRACT:

Background

Modified Vaccinia virus Ankara (MVA) is a safe, highly attenuated orthopoxvirus that is being developed as a recombinant vaccine vector for immunization against a number of infectious diseases and cancers. However, the expression by MVA vectors of large numbers of poxvirus antigens, which display immunodominance over vectored antigens-of-interest for the priming of T cell responses, and the induction of vector-neutralizing antibodies, which curtail the efficacy of subsequent booster immunizations, remain as significant impediments to the overall utility of such vaccines. Thus, genetic approaches that enable the derivation of MVA vectors that are antigenically less complex may allow for rational improvement of MVA-based vaccines.

Principal findings

We have develope

SUBMITTER: Garber DA 

PROVIDER: S-EPMC2674217 | biostudies-literature | 2009

REPOSITORIES: biostudies-literature